388 related articles for article (PubMed ID: 28940058)
21. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
Lee SG; Kim J; Oh MS; Ryu B; Kang KR; Baek J; Lee JM; Choi SO; Kim CY; Chung HM
Biochem Biophys Res Commun; 2021 May; 555():67-73. PubMed ID: 33813278
[TBL] [Abstract][Full Text] [Related]
23. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
Himmel HM
J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
25. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
26. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
[TBL] [Abstract][Full Text] [Related]
27. Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs).
Narkar A; Willard JM; Blinova K
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328619
[TBL] [Abstract][Full Text] [Related]
28. Bufalin-induced cardiotoxicity: new findings into mechanisms.
Li M; Wang XJ; Zhao Q; Wang JX; Xing HY; Zhang YZ; Zhang XX; Zhi YY; Li H; Ma J
Chin J Nat Med; 2020 Jul; 18(7):550-560. PubMed ID: 32616195
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes.
Lu J; Wei H; Wu J; Jamil MF; Tan ML; Adenan MI; Wong P; Shim W
PLoS One; 2014; 9(12):e115648. PubMed ID: 25535742
[TBL] [Abstract][Full Text] [Related]
30. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
[TBL] [Abstract][Full Text] [Related]
31. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
[TBL] [Abstract][Full Text] [Related]
32. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
[TBL] [Abstract][Full Text] [Related]
33. Cardiac Toxicity From Ethanol Exposure in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Rampoldi A; Singh M; Wu Q; Duan M; Jha R; Maxwell JT; Bradner JM; Zhang X; Saraf A; Miller GW; Gibson G; Brown LA; Xu C
Toxicol Sci; 2019 May; 169(1):280-292. PubMed ID: 31059573
[TBL] [Abstract][Full Text] [Related]
34. Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes.
Burnett SD; Blanchette AD; Grimm FA; House JS; Reif DM; Wright FA; Chiu WA; Rusyn I
Toxicol Appl Pharmacol; 2019 Oct; 381():114711. PubMed ID: 31425687
[TBL] [Abstract][Full Text] [Related]
35. The effects of gentamicin and penicillin/streptomycin on the electrophysiology of human induced pluripotent stem cell-derived cardiomyocytes in manual patch clamp and multi-electrode array system.
Hyun SW; Kim BR; Lin D; Hyun SA; Yoon SS; Seo JW
J Pharmacol Toxicol Methods; 2018; 91():1-6. PubMed ID: 29288713
[TBL] [Abstract][Full Text] [Related]
36. A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential.
Palmer JA; Smith AM; Gryshkova V; Donley ELR; Valentin JP; Burrier RE
Toxicol Sci; 2020 Apr; 174(2):218-240. PubMed ID: 32040181
[TBL] [Abstract][Full Text] [Related]
37. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
[TBL] [Abstract][Full Text] [Related]
38. A novel purification method of murine embryonic stem cell- and human-induced pluripotent stem cell-derived cardiomyocytes by simple manual dissociation.
Shinozawa T; Furukawa H; Sato E; Takami K
J Biomol Screen; 2012 Jun; 17(5):683-91. PubMed ID: 22274911
[TBL] [Abstract][Full Text] [Related]
39. The roles of human induced pluripotent stem cell-derived cardiomyocytes in drug discovery: managing in vitro safety study expectations.
Gintant G; Traebert M
Expert Opin Drug Discov; 2020 Jun; 15(6):719-729. PubMed ID: 32129680
[TBL] [Abstract][Full Text] [Related]
40. Human-induced pluripotent stem cell-derived cardiomyocytes from cardiac progenitor cells: effects of selective ion channel blockade.
Altomare C; Pianezzi E; Cervio E; Bolis S; Biemmi V; Benzoni P; Camici GG; Moccetti T; Barile L; Vassalli G
Europace; 2016 Dec; 18(suppl 4):iv67-iv76. PubMed ID: 28011833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
